Clinical Trials Logo

Clinical Trial Summary

This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.


Clinical Trial Description

The objectives of this study are to assess safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) compared to placebo on 1) functional mobility and exercise tolerance, 2) patient-reported physical function, and 3) the inflammatory cytokine biomarker tumor necrosis factor (TNF-alpha). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03169231
Study type Interventional
Source Longeveron Inc.
Contact
Status Completed
Phase Phase 2
Start date July 6, 2017
Completion date September 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT06063590 - A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients Phase 1/Phase 2
Completed NCT02982915 - Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty Phase 1/Phase 2
Completed NCT03071835 - A Comparative Study of Subjects Past Their Final Follow-ON Visit
Completed NCT04314011 - Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty Phase 1/Phase 2